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Summary: Some biochemical characteristics such as substrate specificity, substrate affinity and inhibitor sensitivity
of monoamine oxidase of human blood platelets were investigated. Tyramine, tryptamine and /?-phenylethylamine
were used as substrates. The apparent Michaelis constants, maximal velocity rates and I50 for the inhibitor tranyl-
cypromine were determined. The data were analyzed according to Lineweaver-Burk zndDixon.
The influence of amitriptyline, a prototype of tricyclic antidepressants, on the selected variables (£m, K, I50), was
studied.
The parameters investigated showed remarkably low interindividual differences when healthy volunteers were tested.
The inhibitor activity of amitriptyline towards platelet monoamine oxidase depends on the substrate used. Amitripty-
line concentrations which showed a pronounced effect on the enzyme characteristics are significantly higher than
plasma levels of the drug found under therapeutic conditions.
Kritische Überprüfung der Bestimmung von Monoamin-oxidase in Thrombocyten des Menschen
Zusammenfassung: Einige biochemische Charakteristika wie Substrat-Spezifität, Substrat-Affinität und Inhibitor-
Sensitivität der Monoaminoxidase aus menschlichen Thrombocyten wurden untersucht. Als Substrate dienten Tyra-
min, Tryptamin und 0-Phenylethylamin. Bestimmt wurden die Michaelis-Konstanten, die maximalen Umsatzgeschwin-
digkeiten sowie die Tranylcypromin-Konzentration, die eine 50%ige Hemmung der oxidativen Desaminierung verur-
sacht. Die Meßdaten wurden mit Hilfe von Lineweaver^Burk- und Z^ixöw-Diagrammen ausgewertet. Am Beispiel des
Amitriptylins wurde untersucht, inwieweit tricyelische Psychopharmaka die Monoaminoxidase hemmen und die
gewählten Charakteristika beeinflussen können.
Alle untersuchten Parameter (Km, V, I50) zeigten bemerkenswert geringe interindividuelle Unterschiede bei Bestim-
mungen an gesunden Kontrollpersonen.
Amitriptylin hemmt die Monparninoxidase in Abhängigkeit vom eingesetzten Substrat. Die Amitriptylin-Konzentration,
die einen deutlichen Einfluß auf die gewählten Enzymcharakteristika ausübt, liegt etwa eine Zehnerpotenz über den
Plasmakonzenträtionen des Pharmakons, die üblicherweise unter therapeutischen Bedingungen gefunden werden.
Introduction
The substrate specificity and inhibitor sensitivity of
monoamine oxidase (monoamine: O2 oxidoreductase
(dearninating) EC 1.4.3.4) of human blood platelets
are similar to those of monoamine oxidäse type B from
human brain (1^-4). Since some abnormalities in the
metabolism of biogenic amines in patients with mental
disorders have been postulated (5, 6) several investiga-
tors have tried to correlate the activity of the platelet
monoamine oxidase with the symptomatology and
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classification of mental diseases, thereby implying that
a change of platelet monoamine oxidase may reflect
an alteration of brain monoamine oxidase activity.
Murphy et al (7, 8) using tryptamine found that platelet
monoamine oxidase activity was reduced in chronic
schizophrenics as well as in bipolar depressed patients.
Nies et al (9), using benzylamine as substrate, reported
*) A preliminary report of this study was presented at the 1st
European Neurosciences Meeting, Munich, September 28,
1975.
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an increased platelet monoamine oxidase activity during
depression in schizophrenic patients. However, Friedman
et al (10) and also Shaskan & Becker (11) could not
detect any alteration in monoamine oxidase activity in
psychiatric patients. Most studies hitherto refer to the
activity of the enzyme at a single substrate concentra-
tion only, whereas enzymic kinetic constants e. g.
maximal velocity rate (V) and Michaelis constant (K^
have rarely been published. Data on substrate specifi-
city, substrate affinity and inhibitor characteristics
determined simultaneously are not available. According
to our working hypothesis, some properties of mono·;
amine oxidase and other enzymes involved in the meta-
bolic pathway of biogenic amines might be altered in
patients with manic depressive disorders. It is therefore
necessary to determine ATm, K and I50 simultaneously.
Thus a differentiated method is required which can be
used under clinical routine conditions.
Evidence for the existence of isoenzymes of monoamine
oxidase B is very weak (12). On the other hand, there is
evidence that the enzyme has several catalytic sites (13).
We therefore used three different substrates, tyramine,
tryptamine and phenylethylamine.
Tricyclics appear to influence the enzyme activity in
vitro under special experimental conditions (8,13,14).
The effect of try cyclic antidepressive drugs on the
kinetic parameters of platelet monoamine oxidase was
therefore also examined.
Assay procedure of monoamine oxidase with tyramine,
tryptamine and 0-phenylethylamine as substrates
a) The standard assay contained in a final volume of 2.0 ml:
platelet rich plasma/buffer mixture 1.2 ml;
tyramine 0.02-0.1 ml (corresponding to 10 μ mo 1/1 to
50 μηιοΐ/l); 0.05 ml [14CJtyramine (50 nCi, corresponding to
2.7 μιηοΐ/ΐ);
tryptamine 0.025-0.1 ml (corresponding to 2.5 μιηοΐ/lto
25.5 μηιοΐ/ΐ); 0.05 ml [14C]tryptamine (50 nCi, corresponding
to 0.5 μιηοΐ/ΐ);
^•phenylethylamine 0.015 ml-0.05 ml (15 nCi to 50 nCi,
corresponding to 0.7 μιηοΐ/lto 2.5 μιηοΐ/l);
serotonin 0.01-0.1 ml (corresponding to 10 μηιοΐ/lto
100 μιηοΐ/ΐ); 0.05 mi t14C]serotonin(50 nCi, corresponding
to 0.51 μπιοΐ/l);
phosphate buffer 0.1 mol/1; pH 7.4.
Samples were incubated in plastic tubes for 30 min (tyramine,
tryptamine, serotonin), or for 20 min (phenylethylamine) at
37°C in a Dubnoff shaker under air. The reaction was stopped
by the addition of 0.25 ml of 4 mol/1 HCL The mixture was
transferred to 10 ml glass stoppered centrifuge tubes containing
5 ml of a toluene/ethyl acetate mixture (volumes, 2.5 ml
+ 2.5 ml). The samples were shaken for 10 minutes in a
mechanical shaker. After centrifugation a 3.0 ml aliquot of
the supernatant fluid was transferred to a scintillation
counting vial containing 10 ml of a toluene scintillation
cocktail. The radioactivity of samples was determined by
liquid scintillation spectroscopy in a Packard liquid scintilla-
tion counter at an efficiency for 14C of 90%. Blanks were
obtained from each determination by adding HC1 to the
assay mixture prior to the incubation.
Protein concentrations were measured by the method of
Lowry et al (15). In control experiments it was established
that platelet free plasma did not contain noteworthy mono-
amine oxidase activity towards the substrates mentioned.
b) For the evaluation of Iso the samples were preincubated for
10 min at 37°C at four different inhibitor concentrations
(tranylcyprqmine from 0.02 μιηοΐ/ΐ to 0.15 μηϊοΐ/ϊ). There-
after the enzyme activity was determined using constant
substrate concentrations: tyramine 27.1 μτηοΐ/ΐ;
tryptamine 10.5 μηιοΙ/1; -phenylethylamine 2.5 μπιοΐ/ΐ.
Methods
Preparation of platelet rich plasma
Blood samples were collected at 9 a. m. by dropping venous '
blood (ca. 25 ml) from the cannula into plastic tubes containing
5 ml of ACD-stabilizer (USPx VIII formula B) as the anticoagulant.
The samples were centrifuged for 30 minutes at 180# at 25°C.
A constant aliquot of platelet rich plasma (10 ml) was removed,
using a plastic syringe. Thereafter the number of platelets was
counted. Aliquots of 0.2 ml platelet rich plasma were added to
1.0 ml of phosphate buffer (0.1 mol/1; pH 7.4). These platelet
rich plasma buffer mixtures are stored at — 20°C and used
directly for monoamine oxidase determinations. Under these
conditions no loss in monoamine oxidase activity could be
detected within four weeks. Monoamine oxidase activities are
expressed as nanomoles of deaminated products formed per
10* of platelets per hour.
Materials
Tyramine hydro chloride and tryptamine hydro chloride were
obtained from EGA-Chemie, Steinheim; 0-phenylethylamine
and serotonin-creatininsulfate from Merck, Darmstadt; trans-
2-phenylcyclopropylamine hydrochloride (Tranylcypromine)
from Sigma; |l-r4Cltyramine hydrochloride 9.2 Ci/mol,
Isidechain 2-l4C]tryptaminebisuccinate 53 Ci/mol, 5-hydroxy-
tryptamine binoxolate ([2-14Clserotoninbinoxolate), 48 Ci/mol
and [14CJ0-phenylethylarnine hydrochloride 9.86 Ci/mol, from
NEN, Dreieichenhain, amitriptyline hydrochloride (5-(3-dimethyl-
amino-propyliden)-dibenzo[a, d][l, 4]cycloheptadiene HC1) was
a gift from Sharp and Dohme, Munich.
c) In order to determine the influence of amitriptyline on the
Km and Kvalues of the different substrates, the platelet
samples were preincubated for 10 min at 37°C with different
concentrations according to the standard assay a.
To study the influence of amitriptyline on the I50 of tranyl-
cypromine, the preincubatkm was performed in the presence
of amitriptyline (1 jirnol/l; 10 μηαοΐ/ΐ) and tranylcypromine,
after which the procedure was continued according to b.
The Michaelis constant (K„^ and the maximal velocity rate
(V) were calculated by aLineweaver-Burk diagram, the 50%
inhibition (ISo) was also determined graphically by inter-
polation from curves of percentage inhibition against pi.
Results
Serotonin (10 μτηοΐ/ΐ), which is a good substrate for
monoamine oxidase A, showed very low rate of oxida-
tion with platelet monoamine oxidase, amounting to 1
to 2% of that with tryptamine.
As we used platelet rich plasma as the enzyme source,
benzylamine was not used as a substrate, because it
shows a high rate of oxidation by serum amine oxidase.
In agreement with previous studies (12,13) monoamine
oxidase activity was found to be linear in Lineweaver-
Burk plots (16) for'tyramine and tryptamine between
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1 μπιοΙ/1 and 100 μτηοΐ/ΐ. With phenylethylamine, how-
ever, substrate inhibition occurs at molar concentrations
higher than 10 μηκ>1/1 (fig. 1). Therefore, the kinetics
of phenylethylamine must be determined with substrate
concentrations that give a linear Lineweaver-Burk plot.
Linearity was obtained even when more than 10% of
the substrate was converted to product^ i. e. under con-
ditions for which the Michaelis Menten equation is not
correctly fulfilled.
Figure 2 shows that the mechanism of monoamine
oxidase inhibition by tranylcypromine is the same for
tyramine, tryptamine, and phenylethylamine
respectively. However, the Dixon plot (17) usually taken
for the determination of the inhibition constant K-
does not yield straight lines but hyperbolic ones. From
such inhibition curves the K\ value cannot be graphically
determined. Therefore it is better to take the fifty percent
inhibition Iso as an inhibitor parameter. '
As can be seen from figure 3 there is no great difference
in the tranylcypromine inhibition curves and the I50 of
the three substrates for the platelet monoamine oxidase
of healthy persons. Lineweaver-Burk plots for platelet
monoamine oxidase activity obtained with blood samples
from seven healthy persons (24-49 years) using tyramine
as substrate are shown in figure 4. This diagram demon-
ine] »Ά«1»1!—"LPhenylethylaminej
Fig. 1. Lineweaver-Burk plot of deamin tion of 0-phenylethyl-
amine by platelet monoamine oxidase. Experimental
details are presented in Methods.
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Fig. 3. Inhibition of platelet monoamine oxidase by tranyl-
cypromine when the substrates tyramine (Δ—Δ),
tryptamine (·—o) and 0-phenylethylamine (a—o)
were used. Experimental details are presented in Methods.
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Fig. 2. Dixon plot for the inhibition of platelet monoamine
oxidase by varying amounts of tranyicypromine using
tyiamine, tryptamine and 0-phenylethylamine as
substrates. Tyramine 5.3 μήίρΐ/ΐ (·—-·) and 7.7 μήιοΙ/1
(ο—ο) tryptamine 1.0 μιηοΐ/ΐ (*—*) and 1.5 μηιοΐ/ΐ
(Δ—Δ) ^ -phenylethylamine 1.0 μιηοΐ/l (·—·) and
2.5 μϊηοΐ/ΐ (α-^ο) incubation in the presence of varying
amounts of tranylcypromine. Experimental details are
presented in Methods.
1.4 -
-0.02-0.01 0.09
Γ .Uyramme
Fig. 4. Lineweaver-Burk plot of deamin tion of tyramine by
platelet monoamine oxidase from different healthy
persons. The assay conditions used were the same as
described in Methods.
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Tab. 1. Enzyme characteristics of platelet monoamine oxidase
in healthy persons (n = 14).
[μπιοΐ/ΐ]
x± s
V Iso[nmol/108 (tranyl-
platelets · h) cypromine)
[nmol/1]
x± s x ± s
tyiamine
tryptamine
phenylethylamine
59 ± 10 8.9 ± 2.0
7.4 ± 1.7 1.1 ± 0.3
1 ± 0.35 5.2 ± 2.8
50 ±19
62 ±20
70 ±25
Age ± S. D. of normal control subjects:
men (n = 6): 35.3 ± 7 (from 29 to 49 years)
women (n = 8): 31.5 ± 7.5 (from 24 to 49 years)
strates the small interindividual variation of K^ -values
even in platelet samples having low enzyme activity.
The table presents F, Km and l$o values obtained with
the platelet monoamine oxidase of 14 healthy persons
(male and female). The Km values are in good agree-
ment with those reported by other groups (10, 12, 13).
The reference system for K is nanomol of deaminated
product per 108 platelets. No sex differences of mono-
amine oxidase activity could be found in this small
group. The standard deviation in interindividual values
is remarkably low.
Amitriptyline has a marked influence on the Michaelis
constants and on the K values of all three substrates only
when the concentration is higher than 10 μπιοΐ/ΐ (fig. 5,
Fig. 6. Lineweaver-Burk plot for the inhibition of platelet mono-
amine oxidase by varying amounts of amitriptyline using
tryptamine as substrate. Experimental details are presented
in Methods.
Without amitriptyline (G—o)
Amitriptyline 1 μηιοΐ/ΐ (Δ—Δ)
5 μηιοΐ/l (ο-—ο)
10 jumol/1 (·—·)
20 μηιοΙ/1 (Α—Α)
50 μπιοΐ/ΐ (·—·)
6, 7). But the monoamine oxidase inhibition caused by
tranylcypromine is increased by lower concentrations
of the antidepressive drug. Thereby the I50 falls by half
at an amitriptyline concentration of about 10 μτηοΐ/ΐ.
However, this additional inhibition is more distinct in
the presence of lower concentrations of tranylcypromine
e. g, 40 nmol/1 compared with 75 nmol/1 (fig. 8).
3 0.02
Γ 1 1
.Iyraminer
m 0.06 Ο.ΟΘ
[l / jampl] ·-
Fig. 5. Lineweaver-Burk plot for the inhibition of platelet
monoamine oxidase by varying amounts of amitriptyline
Hising tyramine as substrate. Experimental details are
presented in Methods.
Without amitriptyline (α^-α)
Amitriptyline 1 μπιοΙ/1 (Δ—Δ)
5 μηιοΐ/l (ο—ο)
10 μιηοΐ/l (α—π)
25 μηιοΐ/ΐ (Α—Α)
50 μιηοΐ/ΐ («—β)
-1
Fig. 7. Lineweaver-Burk plot for the inhibition of platelet mono-
amine oxidase by varying amounts of amitriptylihe .using
^phenylethylamine as substrate. Experimental deta s are
presented in Methods.
Without amitriptyline (O^-D)
Amitriptyline 1 μηιοΙ/1 (Δ—Δ)
5 μπιοΙ/1 (ο-^ο)
10 μπιοΐ/l (·—·)
50 μηιοΙΛ ί·^ ··)
J. Clin. Chem. Clin. Biochem. / Vol. 14,1976 / No. 9
Honecker, Christ, M ller-Oerlinghauseh and Coper: Critical evaluation of platelet monoamine oxidase in man 457
100
80
60
1*0
20
Tyro mine Tryptomine Phenylethylomine
0.01 0.1 0.01
ITronylcypromine] (jLimol/l) 0.1 0.01 0.1
Fig. 8. The influence of amitriptyline on the inhibition of platelet monoamine oxidase by tranylcypromine, when the substrates
tyramine, tryptamine and /3-phenylethylamine were used. Experimental details are presented in Methods.
Without amitriptyline (*—*)
Amitriptyline 1 μηιοΐ/ΐ (ο—ο)
10μπιο1/1(·—·)
Discussion
Experimental references to platelet monoamine oxidase
activity in psychiatric patients are controversial, although
similar methods have been used (7—11). The discrepancies
could be explained to some extent by the fact that in
most of the studies only one single substrate concentra-
tion was used. Figure 9, by means of two flctive Line-
weaver-Burk plots, exemplifies why such differences are
possible. The steeper line symbolizes a monoamine
oxid se kinetic of platelets of psychiatric patients, the
other one a kinetic from control persons. If we assume
that in one laboratory the enzyme activity is measured
only with one substrate at the substrate concentration
"x", in a second laboratory at "y"> and in a third one
at "z", the conclusions would be contradictory in
respect to "y". The first investigators would find higher
enzyme activity in patients, the second one no change,
the third one a decreased activity compared to controls.
A further source for the different findings may be the
procedures of isolation and preparation of platelets. It
appears, that the phospholipid content of the mono-
amine oxidase has a marked influence on the enzyme
properties (1). Removal of monoamine oxidase from
its environment by solubilisation procedures, including
ultrasonic and detergent treatment of mitochondria!
preparations, may result in a modification of its pro-
perties (1, 18,19). By treatment of purified platelet
monoamine oxidase with sodium perchlorate in order
to remove the phospholipids from the enzyme, a five
fold increase of the Michaelis constant for phenylethyl-
amine was observed (13).
Phenylethylamine and serotonin are among the substrates
that have been studied with platelet monoamine oxidase.
Some studies have reported that the platelet monoamine
oxidase which is primarily type B (12, 20) most actively
deaminated phenylethylamine, but only showed low
activity for serotonin (12,21,22). Our results are in
agreement with these findings, but they conflict with
those of Youdim et al (23) who found an enzyme activity
for serotonin which was more than twice as high as the
activity for phenylethylamine.
We have noticed substrate inhibition for phenylethyl-
amine in molar concentrations as low as 10 μπιοΐ/ΐ.
Similar results have been found in monoamine oxidase
prepared from porcine brain, where inhibition was
caused by a substrate concentration of about 0.5 mmol/1
(24). Therefore it is necessary to elucidate the kinetic
behaviour of an enzyme-catalyzed reaction before
starting activity measurement with fixed substrate con-
centrations. It is surprising that even in recent publica-
tions on monoamine oxidase activity in platelets, phenyl-
ethylamine was used in millimolar concentrations (23).
potient
control
Fig. 9. Fictive Lineweaver-Burk plots of platelet monoamine-
oxidase activity from patients (D—o) and healthy
control persons (—).
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Assuming that the affinity of the monoamine oxidase to
different substrates is changed in psychiatric patients,
the alteration of the enzyme could be detected by the
determination of the Km but not of the activity,
measured at a single substrate concentration, which
would simulate equal enzyme activity; however,
a complete kinetic study might reveal great differences
in Km and V values. To avoid incorrect interpretations
it is necessary to examine Km and K of each platelet
sample for several monoamine oxidase substrates. In
addition to these constants we measured the I50 (tranyl-
cypromine) of each substrate with the implication that
a change of the Michaelis constant may also reflect an
alteration of the inhibition characteristic.
Recently it has been reported that besides the classical
monoamine oxidase inhibitors other psychoactive drugs
could have some influence on monoamine oxidase activity
(13, 14, 25, 26). Several CNS depressants such as mor-
phine, levallorphon, barbital, and ethanol increase the
deaminating catalysis of monoamine oxidase from rat
brain and bovine brain in the presence of serotonin. This
effect resulted in a change of Km and V. The concentra-
tions required to be effective are about 100 μπιοΐ/ΐ. Also
during long term lithium treatment, an increase in human
platelet monoamine oxidase activity has been observed
byBockar et al (26). Tricyclic antidepressants inhibit
monoamine oxidase in vitro (13,14). The amitriptyline
induced inhibition of platelet monoamirie oxidase was
most pronounced when phenylethylamine was used as
substrate. The inhibition was much weaker using
tryptamine or benzylarnine (13).
Our results show that amitriptyline alters the Fand Km
providing the concentration is higher than 10 /zmol/l;
the I50, however, was considerably affected by amitrip-
tyline at 10 μτηοΐ/ΐ. The plasma levels of amitriptyline
during its therapeutic administration can be assumed
to be not higher than about 1 /zmol/l (27). Therefore,
under clinical conditions tricyclic drugs like amitriptyline
will have no noticeable influence on the parameters
mentioned.
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